September 2025
1. TIBAVIJA SS, Almario MP, Jaramillo V, Rivera J, et al
   Validation and evaluation of the rapid fluorescent focus inhibition test (RFFIT) for the quantification of neutralizing antibodies as an indirect measure of rabies vaccine relative potency: An alternative to the NIH test.
   Vaccine. 2025;64:127724.
   

   >> Share

   
   July 2025
2. ENGLISH S, Fedosyuk S, Orliacq F, Tem V, et al
   Rabies glycoprotein engineering for improved stability and expression.
   Vaccine. 2025;62:127541.
   

   >> Share

   
   June 2025
3. CHOQUE-GUEVARA R, Poma-Acevedo A, Montesinos-Millan R, Sernaque-Aguilar Y, et al
   Chimeric designs of rabies virus glycoprotein G enhance baculovirus pseudotyping and immunogenicity in mice: influence of the transmembrane domain and a flexible linker.
   Vaccine. 2025;61:127404.
   

   >> Share

   
   
4. LIU X, Li J, Zha Y, Wang Z, et al
   The efficacy and safety of SYN023 (Zamerovimab and Mazorelvimab injection), the recombinant humanized anti-rabies virus monoclonal antibody mixture, combined with rabies vaccine in a WHO category III rabies post-exposure population: A randomized, doub
   Vaccine. 2025;61:127289.
   

   >> Share

   
   April 2025
5. LUKA MM, Ferguson EA, Rees E, Hoffu H, et al
   Optimising human rabies vaccine supply chains: A modelling study.
   Vaccine. 2025 Apr 21:127108. doi: 10.1016/j.vaccine.2025.127108.
   

   >> Share

   
   
6. LI G, Cao S, Xu B, Hu J, et al
   Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10-60 years old.
   Vaccine. 2025;53:127082.
   

   >> Share

   
   March 2025
7. DAVIS P, Montroy J, Warshawsky B, Abrams EM, et al
   Immunogenicity of pre-exposure rabies vaccination comparing number of doses and routes of administration: A systematic review and meta-analyses.
   Vaccine. 2025;53:126878.
   

   >> Share

   
   January 2025
8. RITCHIE AJ, Meeyai A, Trotter C, Douglas AD, et al
   Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.
   Vaccine. 2025;47:126703.
   

   >> Share

   
   October 2024
9. PHADKE VK, Gromer DJ, Rebolledo PA, Graciaa DS, et al
   Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults.
   Vaccine. 2024;42:126441.
   

   >> Share

   
   September 2024
10. WADA YA, Mazlan M, Noordin MM, Mohd-Lila MA, et al
    Rabies epidemiology in Malaysia (2015-2023): A cross-sectional insights and strategies for control.
    Vaccine. 2024;42:126371.
    

    >> Share

    
    July 2024
11. JIN F, Zhu L, Wang Y, Qin G, et al
    Corrigendum to "Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic" [Vaccine (2024) 26059].
    Vaccine. 2024 Jul 16:S0264-410X(24)00791-6. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    June 2024
12. JIN F, Zhu L, Wang Y, Qin G, et al
    Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic.
    Vaccine. 2024 Jun 26:S0264-410X(24)00700-X. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
13. QUIAMBAO BP, Payumo RA, Roa C, Borja-Tabora CF, et al
    A phase 2b, Randomized, double blinded comparison of the safety and efficacy of the monoclonal antibody mixture SYN023 and human rabies immune globulin in patients exposed to rabies.
    Vaccine. 2024 Jun 3:S0264-410X(24)00643-1. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    February 2024
14. TOLENTINO JUNIOR DS, Vasconcelos Marques MS, de Oliveira RC
    Rabies vaccination of the Maxakali indigenous population.
    Vaccine. 2024 Feb 26:S0264-410X(23)01542-6. doi: 10.1016/j.vaccine.2023.
    

    >> Share

    
    January 2024
15. CAO H, Li H, Luan N, Zhang H, et al
    A rabies mRNA vaccine with H270P mutation in its glycoprotein induces strong cellular and humoral immunity.
    Vaccine. 2024 Jan 22:S0264-410X(24)00069-0. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    December 2023
16. PICHON S, Moureau A, Petit C, Kirstein JL, et al
    Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax(R) Rabies) administered in a simulated rabies post-exposure regimen in healthy adults.
    Vaccine. 2023 Dec 16:S0264-410X(23)01398-1. doi: 10.1016/j.vaccine.2023.
    

    >> Share

    
    November 2023
17. TECHAKRIENGKRAI N, Aryuman S, Vanlarat K, Karnchanapraphas C, et al
    Impacts of shelter management on canine rabies immune status.
    Vaccine. 2023 Nov 9:S0264-410X(23)01330-0. doi: 10.1016/j.vaccine.2023.
    

    >> Share

    
    
18. HAEDER SF
    Assessing vaccine hesitancy and support for vaccination requirements for pets and potential Spillovers from humans.
    Vaccine. 2023 Nov 5:S0264-410X(23)01263-X. doi: 10.1016/j.vaccine.2023.
    

    >> Share

    
    October 2023
19. MULLER T, Wallace RM, Freuling CM
    Rabies importation in dogs and reduction of waiting period - The fear for scientifically justified changes.
    Vaccine. 2023 Oct 20:S0264-410X(23)01043-5. doi: 10.1016/j.vaccine.2023.
    

    >> Share

    
    
20. HONGTU Q, BoLi L, Jianguo C, Shusheng P, et al
    Immunogenicity of rabies virus G mRNA formulated with lipid nanoparticles and nucleic acid immunostimulators in mice.
    Vaccine. 2023 Oct 20:S0264-410X(23)01191-X. doi: 10.1016/j.vaccine.2023.
    

    >> Share

    
    
21. YU P, Liu Y, Tao X, He Y, et al
    Potential option for rabies post-exposure prophylaxis: New vaccine with PIKA adjuvant against diverse Chinese rabies strains.
    Vaccine. 2023 Oct 9:S0264-410X(23)01161-1. doi: 10.1016/j.vaccine.2023.
    

    >> Share

    
    September 2023
22. LUGELO A, Hampson K, McElhinney LM, Lankester F, et al
    Evaluation of an iELISA for detection and quantification of rabies antibodies in domestic dog sera.
    Vaccine. 2023 Sep 14:S0264-410X(23)01058-7. doi: 10.1016/j.vaccine.2023.
    

    >> Share

    
    July 2023
23. IZUMI F, Miyamoto S, Masatani T, Sasaki M, et al
    Generation and characterization of a genetically modified live rabies vaccine strain with attenuating mutations in multiple viral proteins and evaluation of its potency in dogs.
    Vaccine. 2023 Jul 1:S0264-410X(23)00779-X. doi: 10.1016/j.vaccine.2023.
    

    >> Share

    
    September 2022
24. LI L, Li Y, Bai Y, Li G, et al
    Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: A phase b randomized, double-blind, parallel-controlled study.
    Vaccine. 2022 Sep 16. pii: S0264-410X(22)01114.
    

    >> Share

    
    August 2022
25. QUIAMBAO BP, Lim JG, Bosch Castells V, Augard C, et al
    One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess im
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00923.
    

    >> Share

    
    July 2022
26. QUIAMBAO B, Montalban C, Minutello AM, Guinet-Morlot F, et al
    Serum-free purified Vero rabies vaccine is safe and immunogenic in children: Results of a randomized phaseII pre-exposure prophylaxis regimen study.
    Vaccine. 2022 Jul 26. pii: S0264-410X(22)00830.
    

    >> Share

    
    June 2022
27. PICHON S, Moureau A, Petit C, Chu L, et al
    Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study.
    Vaccine. 2022 Jun 28. pii: S0264-410X(22)00806.
    

    >> Share

    
    
28. WANG L, Zhang J, Meng S, Ge L, et al
    Safety and immunogenicity of human rabies vaccine for the Chinese population after PEP: A systematic review and meta-analysis.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00784.
    

    >> Share

    
    November 2021
29. YE K, Shi D, Zhang Z, Bian L, et al
    A chemiluminescence immunoassay for precise automatic quality control of glycoprotein in human rabies vaccine.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01393.
    

    >> Share

    
    September 2021
30. MCCLAIN JB, Chuang A, Reid C, Moore SM, et al
    Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01114.
    

    >> Share

    
    June 2021
31. ODITA CI, Conan A, Smith-Antony M, Battice J, et al
    Non-specific effects of rabies vaccine on the incidence of self-reported common infectious disease episodes: A randomized controlled trial.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00719.
    

    >> Share

    
    
32. ITO N, Okamoto T, Sasaki M, Miyamoto S, et al
    Safety enhancement of a genetically modified live rabies vaccine strain by introducing an attenuating Leu residue at position 333 in the glycoprotein.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00553.
    

    >> Share

    
    April 2021
33. JENSEN KJ, Tolstrup LK, Knobel DL, Aaby P, et al
    Non-specific effects of maternal and offspring rabies vaccination on mortality and antibiotic use in a Danish pig herd: A randomized trial.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00399.
    

    >> Share

    
    
34. SMITH TG, Fooks AR, Moore SM, Freuling CM, et al
    Negligible risk of rabies importation in dogs thirty days after demonstration of adequate serum antibody titer.
    Vaccine. 2021 Apr 4. pii: S0264-410X(21)00368.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share